PRESS RELEASE: HTL-Strefa Responds to Growing Calls for Affordable Healthcare With Cost-Effective Diabetes Solutions
Amidst recent news on healthcare pricing, HTL-Strefa, part of the MTD Group, reinforces its commitment to delivering innovative, high-quality pen needles at lower costs, with the Droplet brand rapidly expanding across U.S. markets WOODSTOCK, Ga., October 4, 2024 (Newswire.com) – As you may have seen in recent news, there is growing pressure to make healthcare more…
Read MoreMTD Group (parent company of HTL-Strefa, Inc) completes the acquisition of Ypsomed’s Pen Needles and Blood Glucose Monitoring Systems and announces a significant investment plan for its European production sites
Medical Technology and Devices (MTD; www.mtdglobal.com ) is pleased to announce the successful closing of the acquisition of Ypsomed’s Pen Needles and Blood Glucose Monitoring Systems (BGM) businesses, a strategic acquisition initially announced at the end of March. This acquisition marks a major step forward in MTD’s mission to provide superior diabetes and obesity care solutions on…
Read MoreAlternative Solution to Pen Needle Supply Disruption
Dear partner in care of patients with diabetes – We’ve come to learn that there is a significant supply disruption with another leading brand of traditional and safety pen needles. Sudden supply outages for products that deliver life-saving drugs are cause for concern due to the potential impact on adherence to therapy. Supply disruptions also…
Read More